NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $2.34 -0.02 (-0.64%) Closing price 03:59 PM EasternExtended Trading$2.34 +0.00 (+0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LXRX alerts:Sign Up Key Stats Today's Range$2.32▼$2.3950-Day Range$1.88▼$2.6452-Week Range$1.03▼$2.68Volume2.04 million shsAverage Volume2.99 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$4.55Consensus RatingHold Company Overview Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases. The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. In addition to this marketed asset, Lexicon maintains a diversified pipeline with programs spanning metabolic diseases, neuropathic pain, and rare genetic disorders. Key development candidates include small-molecule inhibitors modulating glucose transport and neuroreceptor activity, each designed to address unmet medical needs through precise mechanism-based intervention. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has been publicly traded on the NASDAQ exchange since 2000. The company collaborates with academic institutions, strategic partners and patient advocacy groups to advance its research and expand clinical development globally. With a core scientific team experienced in genomics, medicinal chemistry and clinical development, Lexicon continues to pursue innovative solutions aimed at improving patient outcomes across a variety of therapeutic areas.AI Generated. May Contain Errors. Read More Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat, and ranked 774th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLexicon Pharmaceuticals has a consensus price target of $4.55, representing about 92.4% upside from its current price of $2.37.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to decrease in the coming year, from ($0.17) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -15.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -15.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.58% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 12.46, which indicates bearish sentiment.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXRX Stock News HeadlinesLexicon (LXRX) Q2 2026 Earnings Call Transcript42 minutes ago | finance.yahoo.comLexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 10 at 7:36 PM | seekingalpha.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.August 13 at 1:00 AM | Banyan Hill Publishing (Ad)HC Wainwright Issues Optimistic Outlook for LXRX EarningsAugust 10 at 1:12 AM | americanbankingnews.comWall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to SellAugust 8, 2026 | americanbankingnews.comLexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comLexicon: Q2 Earnings SnapshotAugust 6, 2026 | chron.comLexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA ResubmissionAugust 6, 2026 | quiverquant.comQSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $1.15 on January 1st, 2026. Since then, LXRX stock has increased by 105.7% and is now trading at $2.3650. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.69 million for the quarter, compared to analysts' expectations of $3.99 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 37.53%. Read the conference call transcript. Who are Lexicon Pharmaceuticals' major shareholders? Top institutional investors of Lexicon Pharmaceuticals include Bank of New York Mellon Corp (0.13%). Insiders that own company stock include Raymond Debbane, Invus Global Management, Llc, Lonnel Coats and Jeffrey L Wade. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings8/06/2026Today8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 LXRX's financial health is in the Green zone, according to TradeSmith. LXRX has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Price Target for Lexicon Pharmaceuticals$4.55 High Price Target$6.00 Low Price Target$3.10 Potential Upside/Downside+93.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.34 million Net Margins-147.38% Pretax Margin-147.38% Return on Equity-37.53% Return on Assets-24.96% Debt Debt-to-Equity Ratio0.29 Current Ratio13.37 Quick Ratio13.29 Sales & Book Value Annual Sales$49.80 million Price / Sales21.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book6.04Miscellaneous Outstanding Shares444,960,000Free Float382,662,000Market Cap$1.05 billion OptionableOptionable Beta1.08 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:LXRX) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts